Twentybagger innert eines Monats - was ist hier los? - 500 Beiträge pro Seite
eröffnet am 24.07.15 17:31:06 von
neuester Beitrag 20.05.16 14:27:40 von
neuester Beitrag 20.05.16 14:27:40 von
Beiträge: 5
ID: 1.216.206
ID: 1.216.206
Aufrufe heute: 0
Gesamt: 6.280
Gesamt: 6.280
Aktive User: 0
ISIN: US75081A3095 · WKN: A14T4R
0,0012
USD
0,00 %
0,0000 USD
Letzter Kurs 14.01.21 Nasdaq OTC
Werte aus der Branche Nahrungsmittel
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 63,50 | +71,62 | |
| 11,500 | +21,05 | |
| 78,71 | +18,45 | |
| 1,7500 | +14,38 | |
| 12,390 | +10,04 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,3100 | -17,22 | |
| 1,1400 | -17,39 | |
| 11,840 | -23,42 | |
| 0,6830 | -24,32 | |
| 1,0500 | -50,24 |
Feedback
Ich weiss nicht einmal genau, was die machen,
nur, dass sie in meiner Watchlist von sich reden macht, denn jeden Tag 10 und mehr Prozente Kursgewinn ohne Verschnaufpause fallen irgendwann auch dem blindesten Watchlistenverwalter, nämlich mir, auf...
nur, dass sie in meiner Watchlist von sich reden macht, denn jeden Tag 10 und mehr Prozente Kursgewinn ohne Verschnaufpause fallen irgendwann auch dem blindesten Watchlistenverwalter, nämlich mir, auf...
Biotech, 3D-Druck, Medikamente aus Korallen und irgendetwas gegen Parkinson...
Jetzt bin ich wieder etwas im Bilde.
"Die" Konkurrenz zu ONVO.
RBCC Partner n3D Commercializes New 3D Bioprinting Technology
MIRAMAR BEACH, Fla., Jan 13, 2014 (BUSINESS WIRE) -- Rainbow Coral Corp.’s RBCC +25.00% joint venture partner, Nano3D Biosciences (n3D), has developed the first commercially available 3D bioprinting system designed for high throughput and high-content drug screening, and the global market potential for the device points to very bright future for the company.
3D bioprinting is the process of fabricating biological constructs, typically by dispensing cells on a biocompatible scaffold using a successive layer-by-layer approach in much the same way that a 3-D printer operates. This process can generate tissue-like 3-D structures that are highly useful for clinical testing, assays and experimentation, but the precarious viability of these constructs, combined with their extreme cost, have been a major barrier to widespread adoption of the technology.
New technology developed by n3D may have eliminated these issues, however. RBCC and n3D have joined forces to develop and market the BiO Assay, a new automated toxicity assay system based on magnetic 3D bioprinting. The revolutionary system uses biocompatible magnetic nanoparticles to print cells into 3D structures much faster and more affordably than competing bioprinting tech made by competitors such as Organovo Holdings, Inc. ONVO +5.63% .
In October, a paper describing the innovative system’s use in a study of the effects of ibuprofen and sodium dodecyl sulfate on the viability and migration of human embryonic kidney and tracheal smooth muscle cells was published today by Scientific Reports, the new open-access journal from the highly respected Nature Publishing line.
“We see incredible market potential for this system in the pharmaceutical and CRO industries, where the BiO Assay can be integrated early in the drug discovery process as a compound screen for toxicity and efficacy with minimal turnover,” said RBCC CEO Kimberly Palmer. “We believe that magnetic 3D bioprinting could be the future of regenerative medicine and organogenesis.”
RBCC formed a biotech subsidiary, Rainbow Biosciences, to market and develop new medical and research technology innovations to compete alongside companies such as Biogen Idec Inc. BIIB -2.32% , Abbott Laboratories ABT -0.63% and Amgen Inc. AMGN -1.09% . In 2012, Rainbow Biosciences acquired an equity interest in n3D.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. RBCC +25.00% . The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com . For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html .
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
SOURCE: Rainbow Coral Corp.
Rainbow Coral Corp.Kimberly Palmer, 850-269-7230President and CEO info@rainbowcoral.com
Copyright Business Wire 2014
Jetzt bin ich wieder etwas im Bilde.
"Die" Konkurrenz zu ONVO.
RBCC Partner n3D Commercializes New 3D Bioprinting Technology
MIRAMAR BEACH, Fla., Jan 13, 2014 (BUSINESS WIRE) -- Rainbow Coral Corp.’s RBCC +25.00% joint venture partner, Nano3D Biosciences (n3D), has developed the first commercially available 3D bioprinting system designed for high throughput and high-content drug screening, and the global market potential for the device points to very bright future for the company.
3D bioprinting is the process of fabricating biological constructs, typically by dispensing cells on a biocompatible scaffold using a successive layer-by-layer approach in much the same way that a 3-D printer operates. This process can generate tissue-like 3-D structures that are highly useful for clinical testing, assays and experimentation, but the precarious viability of these constructs, combined with their extreme cost, have been a major barrier to widespread adoption of the technology.
New technology developed by n3D may have eliminated these issues, however. RBCC and n3D have joined forces to develop and market the BiO Assay, a new automated toxicity assay system based on magnetic 3D bioprinting. The revolutionary system uses biocompatible magnetic nanoparticles to print cells into 3D structures much faster and more affordably than competing bioprinting tech made by competitors such as Organovo Holdings, Inc. ONVO +5.63% .
In October, a paper describing the innovative system’s use in a study of the effects of ibuprofen and sodium dodecyl sulfate on the viability and migration of human embryonic kidney and tracheal smooth muscle cells was published today by Scientific Reports, the new open-access journal from the highly respected Nature Publishing line.
“We see incredible market potential for this system in the pharmaceutical and CRO industries, where the BiO Assay can be integrated early in the drug discovery process as a compound screen for toxicity and efficacy with minimal turnover,” said RBCC CEO Kimberly Palmer. “We believe that magnetic 3D bioprinting could be the future of regenerative medicine and organogenesis.”
RBCC formed a biotech subsidiary, Rainbow Biosciences, to market and develop new medical and research technology innovations to compete alongside companies such as Biogen Idec Inc. BIIB -2.32% , Abbott Laboratories ABT -0.63% and Amgen Inc. AMGN -1.09% . In 2012, Rainbow Biosciences acquired an equity interest in n3D.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. RBCC +25.00% . The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com . For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html .
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
SOURCE: Rainbow Coral Corp.
Rainbow Coral Corp.Kimberly Palmer, 850-269-7230President and CEO info@rainbowcoral.com
Copyright Business Wire 2014
Antwort auf Beitrag Nr.: 50.261.130 von ElfenbeinelaufenschnellermitKo am 24.07.15 18:01:17Das dürfte der Grund sein:
http://finance.yahoo.com/news/rbcc-ready-sign-loi-canadian-0…
"letter of intent" bedeutet aber lediglich "Absichtserklärung".
Wenn es dazu nicht kommen sollte, platzt die Blase schneller als man schauen kann.
An der OTC nix neues...
http://finance.yahoo.com/news/rbcc-ready-sign-loi-canadian-0…
"letter of intent" bedeutet aber lediglich "Absichtserklärung".
Wenn es dazu nicht kommen sollte, platzt die Blase schneller als man schauen kann.
An der OTC nix neues...
Anscheinend ein Schwindel gewesen mit den schwindligem Kurs
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -27,27 | |
| +11,54 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 220 | ||
| 112 | ||
| 108 | ||
| 76 | ||
| 44 | ||
| 43 | ||
| 39 | ||
| 35 | ||
| 33 | ||
| 32 |
